Evidence map›Paper›PMID 35084622›Full record

ArticleBreast cancer research and treatment2022

Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.

Changchun Li, Ruiqing Li, Xingchi Hu, Guangjun Zhou, Guoqing Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Changchun Li *Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, Suzhou, 215000, Jiangsu Province, People's Republic of China.
Ruiqing Li *Department of Thyroid and Breast Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou, 225000, People's Republic of China.
Xingchi HuDepartment of Thyroid and Breast Surgery, Yancheng City No. 1 People's Hospital, Yancheng, 224001, People's Republic of China.
Guangjun ZhouDepartment of Thyroid and Breast Surgery, Yancheng City No. 1 People's Hospital, Yancheng, 224001, People's Republic of China.
Guoqing JiangDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, Suzhou, 215000, Jiangsu Province, People's Republic of China. jiang_guoqin@163.com.ORCID http://orcid.org/0000-0002-3474-429X
Nantong University · CNSoochow University · CNYangzhou University · CN

Funding

National Natural Science Foundation of China 81873730the Jiangsu Women and Children Health Key Discipline Program FXK201758the Suzhou Health Planning Commission's Key Clinical Diagnosis and Treatment Program LCZX201606
6 · The paper itself

Abstract

introductionBreast cancer metastasis is the main cause of cancer-related death in women worldwide. Current therapies have remarkably improved the prognosis of breast cancer patients but still fail to manage metastatic breast cancer. Here, the present study was set to explore the role of microRNA (miR)-660 from tumor-associated macrophages (TAMs) in breast cancer, particularly in metastasis. MATERIALS AND

methodsWe collected breast cancer tissues and isolated their polarized macrophages as well as extracellular vesicles (EVs), in which we measured the expression of miR-660, Kelch-like Protein 21 (KLHL21), and nuclear factor-κB (NF-κB) p65. Breast cancer cells were transfected with miR-660 mimic, miR-660 inhibitor, and sh-KLHL21 and then the cells were co-cultured with EVs or TAMs followed by detection of invasion and migration. Finally, mouse model of breast cancer was established to detect the effect of miR-660 or KLHL21 on metastasis by measuring the lymph node metastasis (LNM) foci in femur and lung.

resultsKLHL21 was poorly expressed, whereas miR-660 was highly expressed in breast cancer tissues and cells. Of note, low KLHL21 expression or high miR-660 expression was related to poor overall survival. EVs-contained miR-660 was identified to bind to KLHL21, reducing the binding between KLHL21 and inhibitor kappa B kinase β (IKKβ) to activate the NF-κB p65 signaling pathway. Interestingly, EV-loaded miR-660 from TAMs could be internalized by breast cancer cells. Moreover, silencing of KLHL21 increased the number of lung LNM foci in vivo, while EVs-contained miR-660 promoted cancerous cell invasion and migration. DISCUSSION: Taken altogether, our work shows that TAMs-EVs-shuttled miR-660 promotes breast cancer progression through KLHL21-mediated IKKβ/NF-κB p65 axis.

Indexed as

Breast NeoplasmsExtracellular VesiclesMicroRNAsAnimalsFemaleHumansMacrophagesMiceNF-kappa BMicroRNAsMIRN660 microRNA, humanMIRN-660 microRNA, mouseNF-kappa BBreast cancerExtracellular vesiclesMetastasismicroRNA-660NF-κB p65Tumor-associated macrophages

Identifiers

PMID35084622
OpenAlexW4210726493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.